Sanofi may be a French laboratory, if it finds a vaccine against the new coronavirus, the United States will be served first. The reason? According to its director general, Paul Hudson, the country "shares the risk" of research carried out through a partnership.
In an interview with the Bloomberg agency, Paul Hudson explains that the US government "has the right to the biggest pre-orders", to reward its investment in the search for a vaccine alongside the pharmaceutical giant.
They "will get the vaccines first," he said, because "they have invested to try to protect their people." An advance that will be a few days or weeks on the rest of the world, said the director general of the French laboratory.
More than 100 vaccine projects currently under study
Sanofi, one of the world's leading vaccine specialists, launched the race against the new coronavirus in mid-February, with the announcement of a cooperation agreement with the Authority for Advanced Research and Development in the biomedical field (Barda), which depends on the United States Department of Health.
The lab will use its recombinant DNA technology to "speed up the development of a potential Covid-19 vaccine," he said. To this end, the group has allied with the British GSK, a collaboration whose two laboratories hope to obtain a result by 2021.
In addition, the French laboratory is also collaborating with Translate Bio, an American biotech, which develops drugs based on messenger RNA, with the aim of developing another type of vaccine against Covid-19.
Newsletter - The essentials of the news
Every morning, the news seen by Le ParisienI'm registering
Your email address is collected by Le Parisien to allow you to receive our news and commercial offers. Find out more
Around the world, more than 100 vaccine projects are currently under study, with ten clinical trials already underway.